A Case Study on 18F-FDG PET/CT Imaging Value in Colorectal Cancer with Subcutaneous, Breast, Kidney, and Muscle Metastases
Asian Oncology Research Journal,
Aim: To describe an unusual case of colorectal cancer with metastases to various extra-abdominal sites, including subcutaneous tissues as an extremely rare clinical event with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) findings.
Presentation of Case: We report a case of 51-year-old female patient with metastases of BRAF V600E mutant colorectal adenocarcinoma to the subcutaneous tissue, left kidney, left breast, lower back, anterior abdominal wall, and gluteal region, which was detected by whole body 18F-FDG-PET/CT. Histopathological examination of excisional specimen of a lumbar subcutaneous nodular mass revealed an adenocarcinoma metastasis with RAS wild type, BRAF V600E mutation. The patient was treated with 12 cycles of FOLFOXIRI combined with bevacizumab regimen for 6 months. Follow-up 18F-FDG-PET/CT after the end of therapy revealed complete metabolic response.
Discussion: Subcutaneous metastasis of colorectal cancer with BRAF V600E mutation is a rare but important phenomenon and has poor prognosis. Triplet chemotherapy plus bevacizumab is the treatment of choice due to its aggressive type of tumor. 18F-FDG-PET/CT is a very effective imaging modality to demonstrate all malignant masses before treatment and to evaluate treatment response.
Conclusion: It is essential to be familiar with the rare association of colorectal cancer and breast, kidney, muscle, and subcutaneous metastases to improve diagnostic accuracy and patient management. 18F-FDG-PET/CT imaging is very effective to demonstrate all malignant masses before treatment and to exclude the coexistence of another possible primary tumors via treatment results.
- Atypical rectal cancer metastases
- BRAF V600E mutation
- triplet chemotherapy plus bevacizumab
How to Cite
DOI: 10.1097/RLU.0b013e3181d19084. PMID: 20305419
Tan KY, Ho KS, Lai JH, Lim JF, Ooi BS, Tang CL, Eu KW. Cutaneous and subcutaneous metastases of adenocarcinoma of the colon and rectum. Ann Acad Med Singapore. 2006;35:585–587.
Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol. 1993;29:228–236.
Chen LB, Tong JL, Song HZ, Zhu H, Wang YC. (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol. 2007; 7;13:5025-9.
DOI: 10.3748/wjg. v13.i37.5025.
Faneyte IF, Dresen RC, Edelbroek MA, Nieuwenhuijzen GA, Rutten HJ. Pre-operative staging with positron emission tomography in patients with pelvic recurrence of rectal cancer. Dig Surg. 2008;25:202-7.
Hasegawa H, Nagata Y, Sakakibara Y, Miyake M, Mori K, Masuda N, Mano M, Nakazuru S, Ishida H, Mita E. Breast metastasis from rectal cancer with BRAF V600E mutation: a case report with a review of the literature. Clin J Gastroenterol. 2020;13:153-157.
Clancy C, Burke JP, Kalady MF. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis. 2013; 15:e711–8.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306-15.
Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol. 1993;29:228-36.
Lee TG, Lee SJ. Unusual case of solitary perineal subcutaneous metastasis from sigmoid colon cancer. Ann Coloproctol. 2013;29:34-7.
Lookingbill DP, Spangler N, Sexton FM. Skin involvement as the presenting sign of internal carcinoma: a retrospective study of 7316 cancer patients. J Am Acad Dermatol. 1990;22:19-26.
Damron TA, Heiner J. Distant soft tissue metastases: a series of 30 new patients and 91 cases from the literature. Ann Surg Oncol. 2000;7:526-34.
Plaza JA, Perez-Montiel D, Mayerson J, Morrison C, Suster S. Metastases to soft tissue: a review of 118 cases over a 30-year period. Cancer. 2008;112:193-203.
Krathen RA, Orengo IF, Rosen T. Cutaneous metastasis: a meta analysis of data. South Med J. 2003;96:164-7.
Herrera-Ornelas L, Petrelli N, Mittelman A. Subcutaneous metastases without visceral metastases from an adenocarcinoma of the rectum. Dis Colon Rectum. 1985; 28:523-5.
Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott F, Brown S, Adams R, Maughan T, Quirke P, Cheadle J, Seymour M, Middleton G. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol. 2017;28:562-568.
Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012;7(10):e47054. DOI: 10.1371/journal.pone.0047054.
Cohen R, Cervera P, Svrcek M, Pellat A, Dreyer C, de Gramont A, André T. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? Curr Treat Options Oncol. 2017;18:9.
Camci C, Turk HM, Buyukberber S, Karakok M, Koruk M, Beyazity Y, Inaloz HS. Colon carcinoma with synchronous subcutaneous and osseous metastasis: a case report. J Dermatol. 2002 Jun;29(6):362-5.
DOI: 10.1111/j.1346-8138.2002.tb00282.x. PMID: 12126074.
Kijima S, Sasaki T, Nagata K, Utano K, Lefor AT, Sugimoto H. Preoperative evaluation of colorectal cancer using CT colonography, MRI, and PET/CT. World J Gastroenterol. 2014;20(45):16964-16975.
Abstract View: 72 times
PDF Download: 28 times